Literature DB >> 32115416

High Intravascular Signal Arterial Transit Time Artifacts Have Negligible Effects on Cerebral Blood Flow and Cerebrovascular Reserve Capacity Measurement Using Single Postlabel Delay Arterial Spin-Labeling in Patients with Moyamoya Disease.

M Fahlström1, A Lewén2, P Enblad2, E-M Larsson2, J Wikström2.   

Abstract

BACKGROUND AND
PURPOSE: Arterial spin-labeling-derived CBF values may be affected by arterial transit time artefacts. Thus, our aim was to assess to what extent arterial spin-labeling-derived CBF and cerebrovascular reserve capacity values in major vascular regions are overestimated due to the arterial transit time artifacts in patients with Moyamoya disease.
MATERIALS AND METHODS: Eight patients with Moyamoya disease were included before or after revascularization surgery. CBF maps were acquired using a 3D pseudocontinuous arterial spin-labeling sequence, before and 5, 15, and 25 minutes after an IV acetazolamide injection and were registered to each patient's 3D-T1-weighted images. Vascular regions were defined by spatial normalization to a Montreal Neurological Institute-based vascular regional template. The arterial transit time artifacts were defined as voxels with high signal intensity corresponding to the right tail of the histogram for a given vascular region, with the cutoff selected by visual inspection. Arterial transit time artifact maps were created and applied as masks to exclude arterial transit time artifacts on CBF maps, to create corrected CBF maps. The cerebrovascular reserve capacity was calculated as CBF after acetazolamide injection relative to CBF at baseline for corrected and uncorrected CBF values, respectively.
RESULTS: A total of 16 examinations were analyzed. Arterial transit time artifacts were present mostly in the MCA, whereas the posterior cerebral artery was generally unaffected. The largest differences between corrected and uncorrected CBF and cerebrovascular reserve capacity values, reported as patient group average ratio and percentage point difference, respectively, were 0.978 (95% CI, 0.968-0.988) and 1.8 percentage points (95% CI, 0.3-3.2 percentage points). Both were found in the left MCA, 15 and 5 minutes post-acetazolamide injection, respectively.
CONCLUSIONS: Arterial transit time artifacts have negligible overestimation effects on calculated vascular region-based CBF and cerebrovascular reserve capacity values derived from single-delay 3D pseudocontinuous arterial spin-labeling.
© 2020 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32115416      PMCID: PMC7077908          DOI: 10.3174/ajnr.A6411

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  38 in total

Review 1.  Perfusion imaging of cerebrovascular reserve.

Authors:  Clifford J Eskey; Pina C Sanelli
Journal:  Neuroimaging Clin N Am       Date:  2005-05       Impact factor: 2.264

2.  Pseudocontinuous arterial spin labeling perfusion magnetic resonance imaging--a normative study of reproducibility in the human brain.

Authors:  Wen-Chau Wu; Shu-Fen Jiang; Shun-Chung Yang; Shu-Hua Lien
Journal:  Neuroimage       Date:  2011-03-06       Impact factor: 6.556

3.  Noninvasive method for mapping CVR in moyamoya disease using ASL-MRI.

Authors:  Tomoyuki Noguchi; Masatou Kawashima; Masashi Nishihara; Yoshiaki Egashira; Shinya Azama; Hiroyuki Irie
Journal:  Eur J Radiol       Date:  2015-03-18       Impact factor: 3.528

4.  Partial volume correction in arterial spin labeling using a Look-Locker sequence.

Authors:  Jan Petr; Georg Schramm; Frank Hofheinz; Jens Langner; Jörg van den Hoff
Journal:  Magn Reson Med       Date:  2012-12-27       Impact factor: 4.668

5.  A linear mixed perfusion model for tissue partial volume correction of perfusion estimates in dynamic susceptibility contrast MRI: Impact on absolute quantification, repeatability, and agreement with pseudo-continuous arterial spin labeling.

Authors:  André Ahlgren; Ronnie Wirestam; Emelie Lind; Freddy Ståhlberg; Linda Knutsson
Journal:  Magn Reson Med       Date:  2016-06-20       Impact factor: 4.668

Review 6.  Consensus statement on current and emerging methods for the diagnosis and evaluation of cerebrovascular disease.

Authors:  Manus J Donahue; Eric Achten; Petrice M Cogswell; Frank-Erik De Leeuw; Colin P Derdeyn; Rick M Dijkhuizen; Audrey P Fan; Rashid Ghaznawi; Jeremy J Heit; M Arfan Ikram; Peter Jezzard; Lori C Jordan; Eric Jouvent; Linda Knutsson; Richard Leigh; David S Liebeskind; Weili Lin; Thomas W Okell; Adnan I Qureshi; Charlotte J Stagg; Matthias Jp van Osch; Peter Cm van Zijl; Jennifer M Watchmaker; Max Wintermark; Ona Wu; Greg Zaharchuk; Jinyuan Zhou; Jeroen Hendrikse
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-17       Impact factor: 6.200

7.  Arterial spin labeling for acute stroke: practical considerations.

Authors:  Greg Zaharchuk
Journal:  Transl Stroke Res       Date:  2012-04-14       Impact factor: 6.829

8.  Territorial arterial spin labeling in the assessment of collateral circulation: comparison with digital subtraction angiography.

Authors:  Soke Miang Chng; Esben Thade Petersen; Ivan Zimine; Yih-Yian Sitoh; C C Tchoyoson Lim; Xavier Golay
Journal:  Stroke       Date:  2008-10-09       Impact factor: 7.914

9.  Long-Delay Arterial Spin Labeling Provides More Accurate Cerebral Blood Flow Measurements in Moyamoya Patients: A Simultaneous Positron Emission Tomography/MRI Study.

Authors:  Audrey P Fan; Jia Guo; Mohammad M Khalighi; Praveen K Gulaka; Bin Shen; Jun Hyung Park; Harsh Gandhi; Dawn Holley; Omar Rutledge; Prachi Singh; Tom Haywood; Gary K Steinberg; Frederick T Chin; Greg Zaharchuk
Journal:  Stroke       Date:  2017-08-01       Impact factor: 7.914

10.  Monitoring Cerebral Perfusion Changes after Revascularization in Patients with Moyamoya Disease by Using Arterial Spin-labeling MR Imaging.

Authors:  Seunghyun Lee; Tae Jin Yun; Roh-Eul Yoo; Byung-Woo Yoon; Koung Mi Kang; Seung Hong Choi; Ji-Hoon Kim; Jeong Eun Kim; Chul-Ho Sohn; Moon Hee Han
Journal:  Radiology       Date:  2018-05-01       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.